TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength

Abstract T-cell avidity is a major determinant of Adoptive T cell therapy (ACT) efficacy for cancer treatment. However, high-avidity tumor-specific T cells can rarely be isolated from cancer patients, highlighting the need for strategies to enhance the cytotoxic capacity of low-avidity cells. Here,...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Martina Spiga, Alessia Potenza, Zulma Magnani, Stefano Beretta, Barbara Camisa, Laura Conte, Alessia Airaghi, Neda Mohammadi, Laura Perani, Claudio Doglioni, Maurilio Ponzoni, Francesca Sanvito, Chiara Balestrieri, Lucia Sergi Sergi, Oronza A. Botrugno, Giulio Giovannoni, Giovanni Tonon, Danilo Abbati, Chiara Iozzi, Maximilian Reichert, Hana Algul, Arianna Pocaterra, Martina Fiumara, Samuele Ferrari, Alessia Ugolini, Alice Grometto, Giulia Di Lullo, Giovanni Sitia, Giulio Belfiori, Maria Pia Protti, Renato Ostuni, Anna Mondino, Michele Reni, Stefano Crippa, Massimo Falconi, Luigi Naldini, Eliana Ruggiero, Chiara Bonini
Format:	Artigo
Jezik:	Inglês
Izdano:	Nature Portfolio 2026-01-01
Serija:	Nature Communications
Online dostop:	https://doi.org/10.1038/s41467-025-67263-w
Oznake:	Označite Brez oznak, prvi označite!